How to buy Genmab AS stock (GMAB)

Genmab AS is a biotechnology business based in the US. Genmab AS shares (GMAB) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $20.31 – an increase of 0.69% over the previous week. Genmab AS employs 2,635 staff and has a trailing 12-month revenue of around $19.8 billion.

Our top picks for where to buy Genmab AS stock

Buy Genmab AS stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Genmab AS stock price (NASDAQ: GMAB)

Use our graph to track the performance of GMAB stocks over time.

Genmab AS shares at a glance

• Key figures

Information last updated 2024-12-19.

Latest market close	$20.31
52-week range	$19.85 - $32.88
50-day moving average more info button	$22.06
200-day moving average more info button	$26.30
Wall St. target price	$36.56
PE ratio more info button	19.7451
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$1.02

Is it a good time to buy Genmab AS stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Genmab AS price performance over time

Historical closes compared with the close of $20.31 from 2024-12-20

1 week (2024-12-13)	0.69%
1 month (2024-11-22)	-1.65%
3 months (2024-09-20)	-20.45%
6 months (2024-06-21)	-21.97%

1 year (2023-12-22)	-35.40%
2 years (2022-12-22)	-52.89%
3 years (2021-12-22)	39.88
5 years (2019-12-20)	21.7

Is Genmab AS stock undervalued or overvalued?

Valuing Genmab AS stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Genmab AS's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Genmab AS's P/E ratio

Genmab AS's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 20x. In other words, Genmab AS shares trade at around 20x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Genmab AS's PEG ratio

Genmab AS's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.7. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Genmab AS's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Genmab AS's EBITDA

Genmab AS's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $6.9 billion.

The EBITDA is a measure of a Genmab AS's overall financial performance and is widely used to measure a its profitability.

Genmab AS financials

Revenue TTM	$19.8 billion
Operating margin TTM	38.25%
Gross profit TTM	$14.6 billion
Return on assets TTM	10.95%
Return on equity TTM	14.92%
Profit margin	23.7%
Book value	$502.60
Market Capitalization more info button	$12.8 billion

TTM: trailing 12 months

Genmab AS share dividends

We're not expecting Genmab AS to pay a dividend over the next 12 months.

Have Genmab AS's shares ever split?

Genmab AS's shares were split on a 5:1 basis on 30 April 2018 . So if you had owned 1 share the day before before the split, the next day you'd have owned 5 shares. This wouldn't directly have changed the overall worth of your Genmab AS shares – just the quantity. However, indirectly, the new 80% lower share price could have impacted the market appetite for Genmab AS shares which in turn could have impacted Genmab AS's share price.

Genmab AS share price volatility

Over the last 12 months, Genmab AS's shares have ranged in value from as little as $19.85 up to $32.88. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Genmab AS's is 0.859. This would suggest that Genmab AS's shares are less volatile than average (for this exchange).

Genmab AS overview

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin.

Frequently asked questions

null
What percentage of Genmab AS is owned by insiders or institutions?
Currently 0.007% of Genmab AS shares are held by insiders and 8.412% by institutions. How many people work for Genmab AS?
Latest data suggests 2,635 work at Genmab AS. When does the fiscal year end for Genmab AS?
Genmab AS's fiscal year ends in December. Where is Genmab AS based?
Genmab AS's address is: Carl Jacobsens Vej 30, Copenhagen, Denmark, 2500 What is Genmab AS's ISIN number?
Genmab AS's international securities identification number is: US3723032062 What is Genmab AS's CUSIP number?
Genmab AS's Committee on Uniform Securities Identification Procedures number is: 372303206